Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanism of apoptosis activation by Curcumin rescued mutant p53Y220C in human pancreatic cancer
Lakshay Malhotra, Saurabh Sharma, Gururao Hariprasad, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2022) Vol. 1869, Iss. 12, pp. 119343-119343
Open Access | Times Cited: 18

Showing 18 citing articles:

Curcumin in cancer therapy: Exploring molecular mechanisms and overcoming clinical challenges
Wei Wang, Mingqin Li, Lingzhi Wang, et al.
Cancer Letters (2023) Vol. 570, pp. 216332-216332
Closed Access | Times Cited: 53
Lactoferrin-Based Ternary Composite Nanoparticles with Enhanced Dispersibility and Stability for Curcumin Delivery
Xueqi Li, Yiyang He, Sairui Zhang, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 14, pp. 18166-18181
Closed Access | Times Cited: 50
Role of natural products in tumor therapy from basic research and clinical perspectives
Zhisen Wang, Zhengcheng Liu, Jiao Qu, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 2
Open Access | Times Cited: 19
Design, synthesis and biological evaluation of sulfur-containing tetrahydroxanthones as potential anti-tumor agents
Huimin Zheng, Youyi Wang, Yitao Ren, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130154-130154
Closed Access | Times Cited: 1
Curcumin and its novel formulations for the treatment of hepatocellular carcinoma: New trends and future perspectives in cancer therapy
Seyed Mohammadmahdi Meybodi, Pouria Rezaei, Niki Faraji, et al.
Journal of Functional Foods (2023) Vol. 108, pp. 105705-105705
Open Access | Times Cited: 12
Bergenin inhibits growth of human cervical cancer cells by decreasing Galectin-3 and MMP-9 expression
Ravi Chauhan, Lakshay Malhotra, Ashna Gupta, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
The therapeutic potential of natural products for treating pancreatic cancer
Xia He, Ning Wang, Yu Zhang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Anticancer activity of curcumin-loaded nanocarriers: A focus on combined therapeutic modalities
Fatih Şentürk, Huriye Yasar, Anzel Bahadır, et al.
Studies in natural products chemistry (2025), pp. 1-39
Closed Access
The R337C mutation in the p53 oligomerization domain affects the regulatory domain and its ability to bind response elements: Evidence based on structural and biophysical studies.
Alankrita Singh, Lakshay Malhotra, Abhay Mishra, et al.
Archives of Biochemistry and Biophysics (2025), pp. 110381-110381
Closed Access
Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers
Lakshay Malhotra, Alankrita Singh, Punit Kaur, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-14
Open Access | Times Cited: 2
EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis
Xiaokun Liu, Xiao Gao, Yuling Yang, et al.
APOPTOSIS (2024) Vol. 29, Iss. 7-8, pp. 1161-1184
Closed Access | Times Cited: 1
Cellular and epigenetic perspective of protein stability and its implications in the biological system
Nisha Manav, Bimal Prasad Jit, Babita Kataria, et al.
Epigenomics (2024) Vol. 16, Iss. 11-12, pp. 879-900
Closed Access | Times Cited: 1
Circulating necroptosis markers in chronic pancreatitis and pancreatic cancer: associations with diagnosis and prognostic factors
Hanna Belfrage, Krista Kuuliala, Antti Kuuliala, et al.
Pancreatology (2024)
Open Access | Times Cited: 1
Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers
Lakshay Malhotra, Alankrita Singh, Punit Kaur, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Flavonoids as potential reactivators of structural mutation p53Y220C by computational and cell-based studies
Lakshay Malhotra, Punit Kaur, A.S. Ethayathulla
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 18, pp. 9602-9613
Closed Access | Times Cited: 3
Advances in the treatment of pancreatic cancer with traditional Chinese medicine
Zhang Yan-hua, Hui Xu, Yue Li, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 2
Anticancer therapeutic strategies for targeting mutant p53-Y220C
Vitaly Chasov, Damir Davletshin, Elvina Gilyazova, et al.
Journal of Biomedical Research (2023) Vol. 38, Iss. 3, pp. 222-222
Open Access | Times Cited: 1
Taraxasterol regulates p53 transcriptional activity to inhibit pancreatic cancer by inducing MDM2 ubiquitination degradation
Anna Han, Jiajing Liu, Pan Du, et al.
Phytomedicine (2024) Vol. 136, pp. 156298-156298
Closed Access
Page 1

Scroll to top